Pioglitazone Improves In Vitro Viability and Function of Endothelial Progenitor Cells from Individuals with Impaired Glucose Tolerance

BACKGROUND: Evidence suggests that the PPARγ-agonist insulin sensitizer pioglitazone, may provide potential beneficial cardiovascular (CV) effects beyond its anti-hyperglycaemic function. A reduced endothelial progenitor cell (EPC) number is associated with impaired glucose tolerance (IGT) or diabet...

Descripción completa

Detalles Bibliográficos
Autores principales: Spigoni, Valentina, Picconi, Angela, Cito, Monia, Ridolfi, Valentina, Bonomini, Sabrina, Casali, Chiara, Zavaroni, Ivana, Gnudi, Luigi, Metra, Marco, Dei Cas, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489677/
https://www.ncbi.nlm.nih.gov/pubmed/23139771
http://dx.doi.org/10.1371/journal.pone.0048283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489677/
https://www.ncbi.nlm.nih.gov/pubmed/23139771
http://dx.doi.org/10.1371/journal.pone.0048283

Ejemplares similares